Europe Kirsten Rat Sarcoma (KRAS) Market is Expected to Grow at 11.8% in the Forecast Period of 2021 to 2028

Europe Kirsten Rat Sarcoma (KRAS) Market is growing due to growing prevalence of cancer associated with KRAS mutation, increased investment in R&D. increased penetration of novel diagnostic products and enhanced use of KRAS antibody. However, high cost of product may hamper the growth of the market.

Europe Kirsten Rat Sarcoma (KRAS) Market Scenario               

According to Data Bridge Market Research, the market for Kirsten Rat Sarcoma (KRAS) in Germany region has the highest market share. Market leaders are Thermo Fisher Scientific Inc., which accounts an estimated market share of approximately 10-15%. The company has gained outstanding sale through providing smart medical devices. For instance,

  • In September 2020, Thermo Fischer Scientific Inc received FDA approval for the first NGS-based Companion Diagnostic for RET Fusion-Positive Non-Small Cell Lung Cancer. It is now the first and only FDA-approved test of its kind for targeted treatment for RET fusion-positive NSCLC. The approval received would result in the distribution of the diagnostic kit in developing countries of Europe and Asia-Pacific, enhancing the NGS portfolio. It would show positive growth in the market.

Europe Kirsten Rat Sarcoma (KRAS) MarketTrends Impacting the Market

Now the question is which other regions Thermofiser Scientific, Inc., F. Hoffman La Roche Ltd. and Biocartis are targeting? Data Bridge Market Research has estimated a large growth in Germany Kristen Rat Sarcoma (KARS) market and the market leaders targeting U.K., and France to be their next revenue pockets for 2020.

The Kristen Rat Sarcoma (KARS) market is becoming more competitive with companies such as Thermofiser Scientific, Inc., F. Hoffman La-Roche Ltd. and Biocartis as they are the top dominating companies in Kristen Rat Sarcoma (KARS) market. Data Bridge Market Research new reports highlight the major growth factors and opportunities in the Kristen Rat Sarcoma (KARS) market.

For more analysis on the smart medical devices market request for a briefing with our analysts

Europe Kirsten Rat Sarcoma (KRAS) Market Development

  • In January 2020, QIAGEN and Amgen Inc. announced a strategic collaboration to develop blood- and tissue-based companion diagnostics (CDx), respectively, for investigational cancer treatment AMG 510(Sotoranib). AMG 510 is the first KRASG12C inhibitor to advance to the clinic to investigate the treatment of multiple tumor types. This development will increase the demand and will help to diagnose various kind of cancer.

Scope of the Europe Kirsten Rat Sarcoma (KRAS) Market

Kirsten Rat Sarcoma (KRAS) Market is segmented on the basis of countries into the Germany, U.K., France, Italy, Spain, Switzerland, Netherlands, Belgium, Russia, Turkey and rest of Europe.

  • All country based analysis of swabs collection kits market is further analyzed based on further segmentation. On the basis of product, the Kirsten Rat Sarcoma (KRAS) market is segmented into analyzers, reagents and kits, consumables. On the basis of cancer type, the Kirsten Rat Sarcoma (KRAS) market is segmented into breast cancer, colorectal cancer, pancreatic cancer, lung cancer, cervical cancer, prostate cancer, skin cancer, blood cancer, kidney cancer, ovarian cancer and others. On the basis of age group, the Kirsten Rat Sarcoma (KRAS) market is segmented into pediatric and adult. On the basis of application, the Kirsten Rat Sarcoma (KRAS) market is segmented into development of molecular diagnostics, disease diagnostics, drug discovery and development, personalised medicine, predictive, research and development, therapeutic approach/ prognostics and others. On the basis of end user, the Kirsten Rat Sarcoma (KRAS) market is segmented into academic & cancer research institutes, diagnostic laboratories, hospitals, oncology speciality clinics, pharma & biotech companies and others. On the basis of distribution channel, the Kirsten Rat Sarcoma (KRAS) market is segmented into direct tenders, retail sales, and third party distributor

To know more about the study

Key Pointers Covered in Europe Kirsten Rat Sarcoma (KRAS) Market Industry Trends and Forecast to 2028

  • Market Size
  • Top to Bottom Market Analysis
  • Recent Developments for Market Competitors
  • Recent Market Value for Different Countries

Key Market Competitors Covered in the Report

  • Thermo Fisher Scientific Inc.
  • F. Hoffmann-La Roche
  • Biocartis
  • llumina, Inc.
  • Merck KGaA
  • Abbott
  • Agilent Technologies, Inc.

Above are the key players covered in the report, to know about more and exhaustive list of Kirsten Rat Sarcoma (KRAS) market companies, contact us

Research Methodology: Europe Kirsten Rat Sarcoma (KRAS) Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include vendor positioning grid, market time line analysis, market overview and guide, company positioning grid, company market share analysis, standards of measurement, top to bottom analysis and vendor share analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Primary Respondents

  • Demand Side: Clinicians, Healthcare Professionals, Researchers, Academician.
  • Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Related Reports

Browse in Healthcare Category Related Reports@